CN106880597A - A kind of everolimus piece - Google Patents

A kind of everolimus piece Download PDF

Info

Publication number
CN106880597A
CN106880597A CN201510924102.7A CN201510924102A CN106880597A CN 106880597 A CN106880597 A CN 106880597A CN 201510924102 A CN201510924102 A CN 201510924102A CN 106880597 A CN106880597 A CN 106880597A
Authority
CN
China
Prior art keywords
everolimus
piece according
cyclodextrin
hydroxypropyl beta
piece
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510924102.7A
Other languages
Chinese (zh)
Other versions
CN106880597B (en
Inventor
张贵民
陈小伟
郑华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong New Time Pharmaceutical Co Ltd
Original Assignee
Shandong New Time Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong New Time Pharmaceutical Co Ltd filed Critical Shandong New Time Pharmaceutical Co Ltd
Priority to CN201510924102.7A priority Critical patent/CN106880597B/en
Publication of CN106880597A publication Critical patent/CN106880597A/en
Application granted granted Critical
Publication of CN106880597B publication Critical patent/CN106880597B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A kind of everolimus piece, everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN, deoxycholic acid are dissolved in absolute ethyl alcohol, then will be pelletized on this solution pharmaceutically acceptable auxiliary material, are dried, and add mix lubricant compressing tablet to form.Compared with prior art, preparation process is simple of the present invention, dispersion of medicine, smoothly, drug-eluting is rapid for production process.

Description

A kind of everolimus piece
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of everolimus piece.
Background technology
Everolimus is a kind of inhibitor of mTOR (rapamycin mammal target point), one kind of PI3K/AKT passage downstreams Serine threonine kinases.Everolimus is developed at first by Novartis Co., Ltd of Switzerland (Novartis), trade name Certican, Listed in Sweden first within 2003, European market was captured comprehensively in 2006.
FDA ratifies it and is used for the patient of Sutent or Sorafenib treatment advanced renal cell cancer failure, according to the research of Novartis, according to Wei Mosi can slow down the growth of kidney cancer cell, reduce by 67% death rate.By suppressing growth and the propagation of tumour cell, Directly act on tumour cell;By suppressing blood vessel generation, cause tumor vessel to be distributed and reduce and play indirectly-acting (by having Effect suppresses the propagation of the endothelial cell of generation and the VEGF inductions of tumour cell VEGF).
2010, everolimus was approved for preventing the organ rejection of heart and renal transplant recipients.Additionally, except nephrocyte Rejection after cancer and organ transplant, everolimus also carrying out to neuroendocrine tumor, lymthoma, other cancers and The research of tuberous sclerosis, can share as unitary agent or with existing cancer treatment method.
Everolimus, molecular formula:C53H83NO14, molecular weight:958.22, structural formula is as follows:
Everolimus is white to micro-yellow powder, lipophilicity, and solubility is 10 μ g/mL or so in water at 25 DEG C, according to BCS Genealogical classification judgment principle, everolimus belongs to the BCSII class compounds of low-solubility, high osmosis.Therefore how by system Agent technology improves compound dissolubility to meet dissolution rate and stability requirement, so as to ensure that the product effectively plays its treatment Effect, is finally reached the quality consistent with former triturate, and tool is of great significance and is worth.
Chinese patent CN102138903B discloses a kind of Everolimus solid oral medicinal composition, including everolimus or its The composition of derivative and excipient composition, the pH value of the aqueous solution of the composition is 4~7, the everolimus or its spread out The percentage by weight that biology accounts for the composition is 0.05~5%, main ingredient is carried out by fluid bed technique for packing dispersed. Its shortcoming is complicated preparation technology, and production operation difficulty is big, high cost;Water or other solvents are used in preparation process and is needed Heat, cause the impurity of the drug for preparing greatly, stability is poor.
Chinese patent CN103585122A is carrier material by using hydroxypropyl cellulose, Hydroxypropyl methylcellulose etc., will be according to dimension Department is not prepared into solid dispersions.But it is easy to aging in solid dispersions storing process, causes dissolution rate to reduce;Meanwhile, should Invention has used the toxic solvents such as dichloromethane, chloroform, methyl alcohol, there is potential safety hazard.
Chinese patent CN104721158A carries out micronization processes by by everolimus, then mixes with other auxiliary materials, passes through Dry granulation compressing tablet or direct tablet compressing are prepared from.It is easy to after drug micronization in aggregation, influence mixing uniformity and medicine Dissolution rate.
Be dissolved in TC for everolimus, hydroxypropyl cellulose by Chinese patent CN104666261A, adds Aerosil is adsorbed, then well mixed with pharmaceutically acceptable auxiliary material, is formed using the compacting of direct tablet compressing technique. Due to there is organic solvent TC in preparation, a large amount of aerosil absorption are needed to cause piece weight larger, and There are problems that sticking.
The content of the invention
In view of the deficiencies in the prior art, inventor intend providing a kind of Fast Stripping, be uniformly dispersed, without surfactant Everolimus tablet.
Inventor considers that the purpose for preparing solid dispersions is exactly become because everolimus raw material is crystalline structure first For amorphous.Prior art sticks to prepare everolimus solid dispersions, and if passing through preparation technique by everolimus system It is standby then to reach effect same into amorphous, and in the absence of the aging phenomenon of solid dispersions.
Inventor attempts everolimus dissolving in ethanol, this solution as adhesive being pelletized on auxiliary material, obtains The everolimus piece of same Fast Stripping, but the ethanol solution of everolimus viscosity is smaller, and the mobility of particle of preparation is poor, Content uniformity is big;On this basis, inventor adds various adhesives in above-mentioned solution, although can be prepared into preferably Particle, but in storage process, drug-eluting is substantially slack-off, it may be possible to and the amorphous drug of high-energy is slowly transformed into crystalline state Medicine causes.
Unexpectedly, whether inventor is considered to combine and uses cyclodextrin inclusion technique, and hydroxypropyl is added in above-mentioned solution Betadex, unbodied everolimus inclusion compound is prepared by simple granulation, drying, and using hydroxypropyl again he Cyclodextrin has certain viscosity in ethanol, is used as adhesive, and the mobility of particle for obtaining is good.But, Inclusion compound also occurs the problem that everolimus crystallization is separated out in long-time is placed, and causes drug-eluting slack-off.
Further, if inventor is considered in inclusion compound preparation process, a kind of material is added, is separated out with suppressing crystallization, Effect is might have, by many experiments, inventor, as carrier, not only suppresses drug crystallization from deoxycholic acid, and Dissolution rate can be improved.
Specifically, the present invention is achieved through the following technical solutions:
A kind of everolimus tablet, everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN, deoxycholic acid are dissolved in absolute ethyl alcohol, Then will be pelletized on this solution pharmaceutically acceptable auxiliary material, dried, compressing tablet is formed.
Described everolimus tablet, everolimus is 1 with the weight ratio of HYDROXYPROPYL BETA-CYCLODEXTRIN:5-15.
Preferably, everolimus and the weight ratio of HYDROXYPROPYL BETA-CYCLODEXTRIN are 1:10.
Described everolimus tablet, everolimus is 1 with the weight ratio of deoxycholic acid:3-5.
Preferably, everolimus and the weight ratio of deoxycholic acid are 1:4.
Described everolimus tablet, pharmaceutically acceptable auxiliary material is filler, disintegrant and lubricant.
Described filler be lactose and mannitol in one or two.
Described disintegrant is one or more in PVPP, Ac-Di-Sol and sodium carboxymethyl starch.
Described lubricant is one or more in magnesium stearate, sodium stearyl fumarate and talcum powder.
Compared with prior art, preparation process is simple of the present invention, dispersion of medicine, without exhibiting high surface activating agent, production Smoothly, drug-eluting is rapid for process.
Specific embodiment
Following examples further describe beneficial effects of the present invention, and embodiment is only used for the purpose of illustration, does not limit the present invention Scope, while those of ordinary skill in the art are also contained in this hair according to the obvious change made of the present invention and modification Within the scope of bright.
Embodiment 1
Preparation technology:
Everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN, deoxycholic acid are dissolved in absolute ethyl alcohol, then by this solution in lactose Pelletized with sodium carboxymethyl starch, 40 DEG C of dryings, 20 mesh sieve whole grains add magnesium stearate in dry particl, be well mixed, pressure Piece is formed.
Embodiment 2
Preparation technology:
Everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN, deoxycholic acid are dissolved in absolute ethyl alcohol, then by this solution in lactose Pelletized with Ac-Di-Sol, 40 DEG C of dryings, 20 mesh sieve whole grains add magnesium stearate in dry particl, mixing is equal Even, compressing tablet is formed.
Embodiment 3
Preparation technology:
Everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN, deoxycholic acid are dissolved in absolute ethyl alcohol, then by this solution in sweet dew Pelletized on alcohol and PVPP, 40 DEG C of dryings, 20 mesh sieve whole grains add magnesium stearate in dry particl, be well mixed, pressure Piece is formed.
Embodiment 4
Preparation technology:
Everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN, deoxycholic acid are dissolved in absolute ethyl alcohol, then by this solution in lactose Pelletized with PVPP, 35 DEG C of dryings, 18 mesh sieve whole grains add magnesium stearate in dry particl, be well mixed, compressing tablet Form.
Comparative example 1
Preparation technology:
Everolimus is dissolved in absolute ethyl alcohol, then this solution is pelletized in lactose, 35 DEG C of dryings, 18 mesh sieve whole grains, Magnesium stearate is added in dry particl, is well mixed, compressing tablet is formed.
Comparative example 2
Preparation technology:
Recipe quantity everolimus is taken, is processed through air-flow crushing, make median particle diameter D50 no more than 100 μm, by everolimus It is well mixed with BHT, lactose, HPMC, PVPP, magnesium stearate, compressing tablet is obtained final product.
Comparative example 3
(1) preparation of everolimus solid dispersions
1 part of everolimus
4 parts of absolute ethyl alcohol
0.3 part of hydroxypropyl cellulose
Preparation technology:After everolimus is dissolved in into absolute ethyl alcohol, hydroxypropyl cellulose is added, then stirring and dissolving utilizes Prepared by supercritical fluid technique, by supercritical fluid quick expansion method, solution is passed through nozzle, capillary and depressurize, super to face Boundary's fluid rapid expanding, generates the extremely tiny solid dispersions containing everolimus.
(2) preparation of everolimus piece
Preparation technology:Everolimus solid dispersions and lactose, sodium carboxymethyl starch, magnesium stearate are mixed, compressing tablet is obtained final product. Comparative example 4
Preparation technology:
Everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN are dissolved in absolute ethyl alcohol, then by this solution in lactose and the poly- dimension of crosslinking Pelletized on ketone, 35 DEG C of dryings, 18 mesh sieve whole grains add magnesium stearate in dry particl, be well mixed, compressing tablet is formed.
Comparative example 5
Preparation technology:
Everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN, PVP are dissolved in absolute ethyl alcohol, then by this solution in lactose and Pelletized on PVPP, 35 DEG C of dryings, 18 mesh sieve whole grains add magnesium stearate in dry particl, be well mixed, compressing tablet and Into.
Comparative example 6
Preparation technology:
Everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN, poloxamer are dissolved in absolute ethyl alcohol, then by this solution in lactose Pelletized with Ac-Di-Sol, 35 DEG C of dryings, 18 mesh sieve whole grains add magnesium stearate in dry particl, mixing is equal Even, compressing tablet is formed.
Comparative example 7
Preparation technology:
Everolimus is dissolved in TC, adds hydroxypropyl cellulose, is stirred to dissolve, and adds prescription The aerosil absorption of amount, is then well mixed, using direct with microcrystalline cellulose, PVPP, magnesium stearate Tablet forming technique compacting is formed.
Checking embodiment
1st, dissolution rate
Chromatographic condition:It is filler with octadecylsilane chemically bonded silica;With acetonitrile -5mmol/L potassium dihydrogen phosphates (70: 30) it is mobile phase, 50 DEG C of column temperature, Detection wavelength is 277nm.
Test specimen mentioned above is taken, according to dissolution method (two methods of annex XC second of Chinese Pharmacopoeia 2010 edition), with Water 500ml is dissolution medium, and rotating speed is 50 turns per minute, is operated in accordance with the law, during through 3 minutes, takes solution in right amount, filtration, Subsequent filtrate is taken as need testing solution.Another precision weighs everolimus reference substance about 12.5mg, is placed in 50ml measuring bottles, first Plus acetonitrile 5ml dissolves it, then solubilization goes out medium to scale, shakes up, and precision measures 1ml and is placed in 100ml measuring bottles, Solubilization goes out medium to scale, shakes up, used as reference substance solution.Precision measures each 100 μ l of above two solution, injects liquid Chromatography, records chromatogram, calculates the stripping quantity of every with main peak and isomers peak area sum by external standard method.Limit is The 80% of labelled amount, should meet regulation.
2nd, relevant material
Take this product fine powder appropriate (being approximately equivalent to everolimus 2.5mg), accurately weighed, in putting 10ml measuring bottles, plus acetonitrile is molten Scale is solved and be diluted to, is shaken up, be centrifuged, take supernatant liquid filtering, take subsequent filtrate as need testing solution;Precision is measured for examination Product solution 1ml, in putting 100ml measuring bottles, plus dilution in acetonitrile is to scale, shakes up, used as contrast solution.According to high-efficient liquid phase color Spectrometry (two D of annex V of Chinese Pharmacopoeia version in 2010) is determined, with octadecylsilane chemically bonded silica as filler;Flowing Phase A is 5mmol/L potassium dihydrogen phosphates, and Mobile phase B is acetonitrile;Flow velocity is 1.0ml per minute, linear gradient elution; 55 DEG C of column temperature;Detection wavelength is 277nm.Everolimus peak and isomers peak (relative retention time with main peak is about 1.05) Separating degree should meet regulation, number of theoretical plate is calculated by everolimus peak and is not less than 5000.Precision measures the μ l of contrast solution 20 Injection liquid chromatograph, adjusts detection sensitivity, makes the 20%~25% of the peak height about full scale at principal component peak;It is accurate again Need testing solution and each 20 μ l of contrast solution are measured, liquid chromatograph is injected separately into, chromatogram is recorded.Need testing solution chromatogram If any impurity peaks in figure, in addition to solvent peak and isomers peak (relative retention time with main peak is about 1.05), single impurity Peak area cannot be greater than the 1/5 (0.2%) of contrast solution main peak area, each impurity peak area and cannot be greater than contrast solution master 2 times (2.0%) of peak area.(any peak less than 0.05 times of contrast solution main peak area is negligible in need testing solution)
3rd, uniformity of dosage units
Chromatographic condition:It is filler with octadecylsilane chemically bonded silica;With acetonitrile -5mmol/L potassium dihydrogen phosphates (70: 30) it is mobile phase, 50 DEG C of column temperature, Detection wavelength is 277nm.
Take this product a piece of, in putting 5ml measuring bottles, plus flow phased soln and be diluted to scale, shake up, filter, take subsequent filtrate work It is need testing solution, is determined according to the lower method of assay, calculate content, regulation (Chinese Pharmacopoeia version two in 2010 should be met The E of portion's annex Ⅹ).
Each embodiment measurement result is as follows:
As seen from the table, embodiment of the present invention dissolution is rapid, and uniformity of dosage units preferably, accelerates to investigate, and relevant material is substantially not Become.Comparative example 1, without HYDROXYPROPYL BETA-CYCLODEXTRIN, after acceleration, because raw material is to crystal transfer, causes dissolution to become Slowly;Comparative example 2, and using prior art, by raw material micronization processes, uniformity of dosage units is poor, and dissolution improves not clear It is aobvious;Comparative example 3, and solid dispersions are prepared using supercritical technology, in study on the stability, there are solid dispersions Aging, dissolution is slack-off;Comparative example 4, and without deoxycholic acid, after accelerating to investigate, dissolution rate declines;Contrast is implemented Example 5 is using PVP effect not as the present invention;Comparative example 6 is using poloxamer effect not as the present invention;Contrast is implemented The uniformity of dosage units of example 7 is bad.

Claims (9)

1. a kind of everolimus piece, is made up of everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN and deoxycholic acid.
2. everolimus piece according to claim 1, it is characterised in that it by everolimus, HYDROXYPROPYL BETA-CYCLODEXTRIN, Deoxycholic acid is dissolved in absolute ethyl alcohol, then will be pelletized on this solution pharmaceutically acceptable auxiliary material, is dried, and adds profit Lubrication prescription mixed pressuring plate is formed.
3. everolimus piece according to claim 1, it is characterised in that the weight of everolimus and HYDROXYPROPYL BETA-CYCLODEXTRIN Than being 1:5-15.
4. everolimus piece according to claim 1, it is characterised in that the weight of everolimus and HYDROXYPROPYL BETA-CYCLODEXTRIN Than being 1:10.
5. everolimus piece according to claim 1, it is characterised in that everolimus is 1 with the weight ratio of deoxycholic acid:3- 5, preferably 1:4.
6. everolimus piece according to claim 2, it is characterised in that pharmaceutically acceptable auxiliary material is filler, disintegration Agent and lubricant.
7. everolimus piece according to claim 6, it is characterised in that described filler is in lactose and mannitol Plant or various.
8. everolimus piece according to claim 6, it is characterised in that described disintegrant is PVPP, crosslinking carboxylic One or more in sodium carboxymethylcellulose pyce and sodium carboxymethyl starch.
9. everolimus piece according to claim 6, it is characterised in that described lubricant is rich magnesium stearate, stearic acid One or more in horse acid sodium and talcum powder.
CN201510924102.7A 2015-12-14 2015-12-14 Everolimus tablet Active CN106880597B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510924102.7A CN106880597B (en) 2015-12-14 2015-12-14 Everolimus tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510924102.7A CN106880597B (en) 2015-12-14 2015-12-14 Everolimus tablet

Publications (2)

Publication Number Publication Date
CN106880597A true CN106880597A (en) 2017-06-23
CN106880597B CN106880597B (en) 2022-06-07

Family

ID=59173325

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510924102.7A Active CN106880597B (en) 2015-12-14 2015-12-14 Everolimus tablet

Country Status (1)

Country Link
CN (1) CN106880597B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938584A (en) * 2018-08-17 2018-12-07 湖北欣瑞康医药科技有限公司 A kind of tablet and preparation method thereof of the Tivozanib of inhibitor containing vegf receptor salt
CN112630367A (en) * 2020-12-18 2021-04-09 卓和药业集团有限公司 High performance liquid chromatography analysis method of everolimus

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098875A (en) * 2005-01-05 2008-01-02 特瓦药厂私人有限公司 Amorphous tacrolimus and preparation thereof
CN101115758A (en) * 2005-02-04 2008-01-30 韩美药品株式会社 Amorphous taclolimus solid dispersion having an enhanced solubility and pharmaceutical composition comprising same
CN101361703A (en) * 2008-09-24 2009-02-11 宋洪涛 Sirolimos sustained and controlled release preparation and preparation method thereof
CN101433721A (en) * 2007-11-16 2009-05-20 华中科技大学 Nimesulide-hydroxypropyl-beta-cyclodextrin inclusion compound eye drops and preparation method thereof
CN101664394A (en) * 2009-09-25 2010-03-10 宋洪涛 Tacrolimus sustained-release preparation and preparation method thereof
CN102008429A (en) * 2009-09-25 2011-04-13 宋洪涛 Tacrolimus controlled release preparation and preparation method thereof
US20120041068A1 (en) * 2010-08-11 2012-02-16 Aptapharma, Inc. Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
CN102688243A (en) * 2012-06-18 2012-09-26 中国药科大学 Clathrate compound of perphenazine cyclodextrin derivative, and preparation method thereof
CN102784150A (en) * 2012-09-04 2012-11-21 中国药科大学 Clozapine cyclodextrin inclusion compound and preparation method thereof
EP2537534B1 (en) * 2011-06-22 2014-12-17 Hexal AG Esters of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their therapeutic use.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098875A (en) * 2005-01-05 2008-01-02 特瓦药厂私人有限公司 Amorphous tacrolimus and preparation thereof
CN101115758A (en) * 2005-02-04 2008-01-30 韩美药品株式会社 Amorphous taclolimus solid dispersion having an enhanced solubility and pharmaceutical composition comprising same
CN101433721A (en) * 2007-11-16 2009-05-20 华中科技大学 Nimesulide-hydroxypropyl-beta-cyclodextrin inclusion compound eye drops and preparation method thereof
CN101361703A (en) * 2008-09-24 2009-02-11 宋洪涛 Sirolimos sustained and controlled release preparation and preparation method thereof
CN101664394A (en) * 2009-09-25 2010-03-10 宋洪涛 Tacrolimus sustained-release preparation and preparation method thereof
CN102008429A (en) * 2009-09-25 2011-04-13 宋洪涛 Tacrolimus controlled release preparation and preparation method thereof
US20120041068A1 (en) * 2010-08-11 2012-02-16 Aptapharma, Inc. Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
EP2537534B1 (en) * 2011-06-22 2014-12-17 Hexal AG Esters of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their therapeutic use.
CN102688243A (en) * 2012-06-18 2012-09-26 中国药科大学 Clathrate compound of perphenazine cyclodextrin derivative, and preparation method thereof
CN102784150A (en) * 2012-09-04 2012-11-21 中国药科大学 Clozapine cyclodextrin inclusion compound and preparation method thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938584A (en) * 2018-08-17 2018-12-07 湖北欣瑞康医药科技有限公司 A kind of tablet and preparation method thereof of the Tivozanib of inhibitor containing vegf receptor salt
CN108938584B (en) * 2018-08-17 2021-01-26 湖北欣瑞康医药科技有限公司 Tablet containing VEGF receptor inhibitor Tivozanib salt and preparation method thereof
CN112630367A (en) * 2020-12-18 2021-04-09 卓和药业集团有限公司 High performance liquid chromatography analysis method of everolimus

Also Published As

Publication number Publication date
CN106880597B (en) 2022-06-07

Similar Documents

Publication Publication Date Title
CN103340829B (en) Enteric coating pellet of proton pump inhibitor
CN104306344B (en) A kind of Azilsartan tablet and preparation technology thereof
CN103933000B (en) Azilsartan tablet and preparation method thereof
CN104055743B (en) A kind of preparation method containing razaxaban oral formulations
CN109674754B (en) Flupentixol and melitracen pharmaceutical composition and preparation thereof
CN102846575B (en) Nifedipine sustained release tablet and preparation method thereof
CN106880597A (en) A kind of everolimus piece
CN101632662B (en) Sirolimus preparation and preparation process thereof
CN105147687A (en) Pharmaceutical dasatinib composition capsules for treating leukemia
CN106389428B (en) Composition capable of improving bioavailability and stability of azilsartan and preparation method thereof
CN103494818B (en) Nicotinic acid and simvastatin sustained release tablets and method for manufacturing same
CN103385863B (en) Sodium azulene sulfonate sustained-release preparation
CN106860407A (en) A kind of razaxaban piece
CN104771380A (en) Tacrolimus capsule capable of being rapidly dissolved out
CN104644601B (en) Capecitabine tablet
CN106913538A (en) A kind of Abiraterone acetate sublingual tablets and preparation method thereof
CN104523632B (en) A kind of Azilsartan tablet
CN106309387B (en) Everolimus tablet
CN105616365B (en) A kind of everolimus tablet
CN104666261B (en) A kind of tablet of everolimus
CN115887393B (en) Olmesartan medoxomil tablet and preparation method thereof
CN105106135A (en) Ezetimibe pharmaceutical composition dry suspension for treatment of cardio-cerebral vascular system diseases
CN106880617A (en) A kind of tacrolimus capsules
CN104116719B (en) A kind of huperzine A is adjusted and is released tablet composition and preparation method thereof
CN106913543A (en) A kind of dabigatran etcxilate tablet and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant